Please login to the form below

Not currently logged in
Email:
Password:

diabetic macular edema

This page shows the latest diabetic macular edema news and features for those working in and with pharma, biotech and healthcare.

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.

Latest news

  • Eylea growth closes the gap with Lucentis Eylea growth closes the gap with Lucentis

    Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... visual impairment due to macular oedema resulting from

  • Fresh approval for Roche's Lucentis as competition heats up Fresh approval for Roche's Lucentis as competition heats up

    drug. Lucentis (ranibizumab) has become the first medicine in the US to be cleared to treat diabetic retinopathy in people with diabetic macular edema (DME), which affects around 750, 000 Americans ... Lucentis' approval "gives patients with diabetic

  • Bayer files Eylea for diabetes complication in EU Bayer files Eylea for diabetes complication in EU

    Looks to keep with Novartis’ Lucentis. Bayer is trying to win approval for a third indication for its big-selling eye disease treatment Eylea, namely the treatment of diabetic macular edema ... DME). Eylea (aflibercept) - also known as VEGF Trap-Eye -

  • Lucentis cleared in Europe for pathological myopia Lucentis cleared in Europe for pathological myopia

    Lucentis was originally developed by Genentech - which has US marketing rights - and is already approved for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular ... edema secondary to retinal vein

  • Novartis posts strong Q1 2011 results

    The company's new product for the treatment of vision loss due to diabetic macular edema,  Lucentis (ranibizumab), which was also approved for use in the EU, produced sales worth $444m.

More from news
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...